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ABSTRACT 
Introduction 
Implantable Cardioverter Defibrillators (ICD) have been demonstrated to improve survival in 
cardiac patients with high risk for sudden death. The incidence of ICD implantations is 
increasing worldwide. The cause and nature of death in the ICD population has been 
insufficiently investigated. In 2010 consensus statements were published to address and 
highlight the management of ICD patients who were nearing end of life. The overall aim of 
this thesis was to study patients with implantable defibrillator in end of life as well as 
physicians’ knowledge about ICD treatment and compliance to guidelines concerning ICD 
management. 
 
Methods and Results 
Study I: An observational study exploring intracardiac electrograms from 125 deceased ICD 
patients. Ventricular tachyarrhythmia occurred in 35% of those patients during the last hour 
of their lives, and 31% received shock treatment during the last 24 hours. 52% of the patients 
had a do-not-resuscitate (DNR) order, but still had shock therapy active 24 hours before death 
in 65% of cases. 
Study II: An observational analysis of 65 deceased ICD patients with DNR order. The 
majority (86%) of patients were treated in hospitals, mainly (63%) in university hospitals and 
(33%) in Cardiology wards. Patients had active ICD therapy in 51% of cases despite a DNR 
order, and 24% of those patients experienced shocks as consequence. Patients with active 
ICD therapy had a median of 4 days (IQR 1-38) from decision of DNR to death. In the 38% 
of the patients who had ICD therapy deactivated, the deactivation was performed two days or 
more after the DNR decision.  
Study III: A cross-sectional comparative study with development of a questionnaire that was 
distributed among 432 physicians in 14 hospitals with a response rate of 99.5%. Many (83%) 
of the physicians said they had experience with ICD patients and 68% of physicians rated 
their ICD knowledge to be low. Sufficient knowledge regarding ICD therapy defined 
according to pre-specified criteria was observed in 41%. Physicians in Cardiology 
departments scored significantly higher than others. Only 30% of physicians in Internal 
Medicine and 19% of physicians in Geriatrics reached sufficient knowledge compared with 
71% in Cardiology. 
Study IV: A comparison of two cohorts of ICD patients who died in hospitals before and after 
the implementation of new guidelines. Almost two-thirds of ICD patients in the two groups 
died in wards other than Cardiology. In group 1 patients had a DNR order in 54% compared 
to 73% in group 2. Shock deactivation was present in 52% of the patients in group 1 
compared to 67% in group 2. The difference in deactivation rate between group 1 and 2 was 
  
only significant (p=0.016) for DNR patients treated in Cardiology. A significant difference 
(p=0.038) was also found in deactivation within group 2 between DNR patients treated in 
Cardiology vs. DNR patients in Non-Cardiology.  
 
Conclusions 
Patients with ICD dies in hospitals and the majority are treated in Non-Cardiology wards. 
Approximately one-third of patients with an ICD have ventricular tachyarrhythmia at end of 
life. Many patients have a DNR order but still have shock therapy active and thus receive 
unnecessary shocks before death. Deactivation rates have increased but not significantly since 
publications of international guidelines on the management of ICD in patients at end of life. 
Physicians in Cardiology, Internal Medicine, and Geriatrics have a lack of basic ICD 
knowledge, possibly affecting their ability to manage ICD patients and may increase the risk 
for unnecessary suffering for these patients at end of life. 
  
LIST OF SCIENTIFIC PAPERS 
I. Kinch Westerdahl A, Sjöblom J, Mattiasson A-C, Rosenqvist M, Frykman V. 
Implantable cardioverter-defibrillator therapy before death: high risk for 
painful shocks at end of life.  
Circulation. 2014;129(4):422-9 
 
II. Kinch Westerdahl A, Sutton R, Frykman V. Defibrillator patients should not 
be denied a peaceful death.  
International Journal of Cardiology. 2015;182:440-6 
 
III. Kinch Westerdahl A, Frykman V. Physicians’ knowledge of implantable 
defibrillator treatment. Are we good enough?  
Submitted 
 
IV. Kinch Westerdahl A, Magnsjö J, Frykman V. Deactivation of implantable 
defibrillators at end of life- can we do better? 
Manuscript 
  
CONTENTS 
1 INTRODUCTION .............................................................................................. 1 
1.1 SUDDEN CARDIAC DEATH ................................................................... 1 
1.2 IMPLANTABLE CARDIOVERTER DEFIBRILLATOR ............................ 1 
1.3 ICD THERAPY ........................................................................................ 4 
1.4 COMPLICATIONS ................................................................................... 5 
1.5 ICD KNOWLEDGE .................................................................................. 6 
1.6 CARE IN END OF LIFE ........................................................................... 7 
1.7 LOCATION OF DEATH ........................................................................... 8 
1.8 DO NOT RESUCITATE ........................................................................... 8 
1.9 DEACTIVATION ...................................................................................... 8 
1.10 CAUSE OF DEATH ................................................................................. 9 
2 AIM ................................................................................................................. 11 
3 MATERIAL AND METHODS ......................................................................... 12 
3.1 STUDY I................................................................................................. 12 
3.2 STUDY II................................................................................................ 12 
3.3 STUDY III............................................................................................... 13 
3.4 STUDY IV .............................................................................................. 14 
4 STATISTICAL ANALYSIS .............................................................................. 15 
4.1 ETHICAL CONSIDERATIONS .............................................................. 15 
5 RESULTS ....................................................................................................... 16 
5.1 STUDY I................................................................................................. 16 
5.2 STUDY II................................................................................................ 18 
5.3 STUDY III............................................................................................... 20 
5.4 STUDY IV .............................................................................................. 24 
6 DISCUSSION ................................................................................................. 27 
7 CONCLUSIONS ............................................................................................. 32 
8 CLINICAL IMPLICATIONS............................................................................. 33 
9 FUTURE PERSPECTIVES ............................................................................ 33 
10 SVENSK SAMMANFATTNING...................................................................... 34 
11 ACKNOWLEDGEMENTS .............................................................................. 37 
12 REFERENCES ............................................................................................... 40 
 
  
LIST OF ABBREVIATIONS 
AD Advance directive 
ANOVA Analysis of Variance  
ATP Anti tachycardia Pacing 
CAD Coronary Artery Diseases 
CPR Cardiopulmonary Resuscitation 
CRT Cardiac Resynchronization Therapy 
CRT-D Cardiac Resynchronization Therapy Defibrillator 
EF Ejection Fraction 
EGM Intracardiac Electrograms  
EOL End of Life 
ICD Implantable Cardioverter Defibrillator 
ICU Intensive Care Unit 
IQR Interquartile Range 
NYHA New York Heart Association 
SCD Sudden Cardiac Death 
SD Standard Deviation 
S-ICD Subcutaneous Implantable Defibrillator 
VF Ventricular Fibrillation 
VT Ventricular Tachycardia 
WHO World Health Organization 
QOL Quality of Life 
 
  1 
1 INTRODUCTION 
1.1 SUDDEN CARDIAC DEATH 
Cardiovascular diseases are the number one cause of death throughout the world and are 
responsible for approximately 17 million deaths per year. About 25% of these deaths are 
caused by sudden cardiac death (SCD) 
1-3
. The risk of SCD is higher in men than in women 
and increases with age. This is due to a higher prevalence of Coronary Artery Disease 
(CAD) in older people as well as other chronic heart diseases such as heart failure 
4
. In 
young people, channelopathies, cardiomyopathy and myocarditis are the most common 
causes of SCD 
5
. 
Sudden cardiac death is often caused by a life-threatening arrhythmia such as ventricular 
tachycardia (VT) or ventricular fibrillation (VF), conditions with rapid and uncoordinated 
contractions of ventricles of the heart that make it quiver rather than contract properly. The 
arrhythmia will result in SCD within minutes if not treated. The only way to convert VF is 
to deliver an electrical shock from a defibrillator, externally or internally i.e. with an 
implantable defibrillator (Figure 1). 
 
Figure 1. Historical development of the ICD. Image provided courtesy of Boston Scientific. © 2016 Boston 
Scientific Corporation or its affiliates. All rights reserved. 
1.2 IMPLANTABLE CARDIOVERTER DEFIBRILLATOR 
The Implantable Cardioverter Defibrillator (ICD) was invented by Dr. M. Mirowski and 
implanted in humans for the first time in 1980. He was inspired to develop the ICD after 
one of his colleague suffered from episodes of VT and later died of SCD 
6
. Since then 
several studies have demonstrated improved survival with ICD therapy for selected patient 
groups 
7, 8
. During the past decade, the indication for such therapy has evolved. Today ICD 
are offered as secondary prevention to patients who have survived a prior cardiac arrest or 
sustained VT. In recent years ICD are also offered as primary prevention to individuals 
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without a history of cardiac arrest but with an increased risk of developing life-threatening 
ventricular arrhythmias in the future 
9-12
. The Swedish National Board of Health has given 
primary prevention the same level (level 2 on a scale 1-10) of recommendation as 
secondary prevention 
13
.  
The number of patients who meet the guideline-recommended indications for ICD 
treatment is increasing. The majority of patients today receive their ICD as primary 
prevention. The exact number of active devices in the world is unknown, but recent surveys 
have reported over 130,000 implantations per year in the USA and 70,000-80,000 in 
Europe 
14, 15
. There is a large variation in implantation rates in Europe. The number of ICD 
implantations per million inhabitants in 2013 was more than twice as high in Western 
Europe than in other countries in Eastern Europe due to socio-economical factors (Figure 2)
 
16
. In 2014 there were over 9,000 active ICD patients in Sweden. Sixty-eight percent of all 
new implants were due to primary prevention 
17
. 
 
Figure 2. Implantable Cardioverter Defibrillator (ICD) implantations per million inhabitants in 2013. 
Reproduced from Europace, Raatikainen MJ et al, 2015, 17, i1-75, by permission of Oxford University Press. 
Initially the ICD was implanted surgically in the abdomen and connected to leads fixed to 
the ventricles via thoracotomy. This was a complex procedure with long hospitalization and 
convalescence for the patient. The first ICD had shock as the only therapy option. The 
transvenous approach is now the standard implantation routine and has been for many 
years. One, two or three electrodes are placed trough a vein into the right chambers of the 
heart. In the cases were only one electrode is used, the electrode is inserted in to the right 
ventricle. That system is called single-chamber ICD. Most patients receive a dual-chamber 
ICD where a second lead is inserted to the right atrium (Figure 3). Sometimes patients with 
heart failure and broad QRS may receive an additional left ventricular electrode placed 
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through the coronary sinus into a vein on the left side of the heart. The two ventricular 
electrodes will, by pacing, resynchronize the contractions of the heart’s ventricles. The 
system is called Cardiac Resynchronization Therapy (CRT), and it can be used in 
combination with a defibrillator (CRT-D) 
18
. 
 
Figure 3. Implanted ICD system with one atrial electrode and one high-voltage electrode in the right ventricle 
(illustration by Marianne Westerdahl). 
Recently, a subcutaneous ICD (S-ICD) has been introduced where the pulse generator is 
implanted on the left side of the patient’s thorax, below the axillary, and connected to a 
single lead which is tunneled under the skin (Figure 4). Compared to the ordinary ICD, the 
S-ICD cannot pace and is therefore not appropriate for patients with bradycardia or when 
CRT is considered 
19
. 
 
Figure 4. From abdominal implant, transvenous and subcutaneous ICD. Image provided courtesy of Boston 
Scientific. © 2016 Boston Scientific Corporation or its affiliates. All rights reserved. 
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1.3 ICD THERAPY 
The ICD monitors the heart rhythm continuously. If a life-threatening arrhythmia occurs, 
the ICD promptly identifies it and treats it appropriately according to the ICD’s 
programming. Programming is done within specific VT or VF zones defined by the heart 
rate. The ICD will start to identify and, if appropriate, deliver therapy if the arrhythmia is 
above the programmed heart rate. If the arrhythmia is identified as a VT, the ICD is usually 
programmed to terminate the arrhythmia with anti-tachypacing (ATP) as the first line of 
treatment. The ATP is a number of pacing stimuli given at a faster rate than the arrhythmia 
itself 
18
. 
If the ICD identifies the arrhythmia as a VF, or if it is not successful in terminating the 
arrhythmia with ATP, it will deliver a high-voltage electrical shock in the region of 30-40 
Joules (500-800 Volts) (Figure 5). Shock treatment is administered through defibrillator 
coils on the electrode and the can of the ICD 
18
. The ICD will continue to deliver 
consecutive shocks either until the arrhythmia is terminated or until the maximum number 
of shocks for the device has been reached which is up to 6-8 shocks depending on 
manufacturer. Sometimes the arrhythmia starts over again. This is called an arrhythmic 
storm. In these cases, the device can deliver shocks until the battery is completed which 
could result in up to 100-200 shocks. When suffering from an arrhythmic storm the patient 
needs acute medical attention. Patients are instructed to seek medical advice when they 
suffer from a shock to avoid the scenario with multiple shocks 
20
. 
 
Figure 5. Patient with ICD in end of life with ventricular arrhythmia treated with ATP and shock therapy. 
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1.4 COMPLICATIONS 
Appropriate shock therapy – which is lifesaving in many cases – has an annual rate of 6.0-
7.5% 
9, 21
. ICD therapy is generally well-accepted by patients and is associated with 
preserved or improved quality of life when compared with anti-arrhythmic medical 
treatment 
22-24
. However, shock treatment may also lead to distress and sometimes problems 
with device acceptance (Figure 6) 
25
. 
Patients have described ICD shocks as “being hit by a truck,” or “being kicked by a horse” 
and on average have rated them a 6 on a 0-10 pain scale 
26
. Shocks are painful and can 
cause anxiety 
22, 27, 28
. Studies have shown a lower health-related quality of life (QOL) for 
patients who receive shocks, compared with those who do not 
22-24, 29
. Anxiety (8-63%) as 
well as depression (5-41%) are common psychological complications where the occurrence 
of shocks, especially inappropriate shocks, is a risk factor for feeling distressed 
20, 22, 23, 28, 30-
35
. 
 
Figure 6. Continuum of ICD shock response. Reproduced from Heart, Sears SF, Conti JB, 87, 488-93, 2002, 
with permission from BMJ Publishing Group Ltd. 
Furthermore, many patients with an ICD receive inappropriate shocks when the device 
delivers a high-voltage discharge for a reason other than ventricular arrhythmia. Inappropriate 
shocks are most commonly a result of supraventricular tachycardia including sinus 
tachycardia, atrial fibrillation, oversense problems (mostly due to T-waves), or technical 
failure 
36, 37
. The incidence of inappropriate shock varies between 7-24%
12, 21, 36, 38, 39
. 
Recently programming strategies with a more conservative approach (i.e. higher therapy 
zones with longer detection intervals and more ATP therapy) have been applied, further 
contributing to minimizing the risk of inappropriate shocks in the future 
40, 41
. 
Most patients tolerate ICD shocks because of the lifesaving protection provided by the 
device, but 23% dread shocks and 5% say they would rather be without the ICD than receive 
shock treatment 
26
.  
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The survival rates of ICD patients are higher than for those with a regular pacemaker. After 
follow-up of ten years, 66% of ICD patients were still alive compared to 36% of pacemaker 
patients 
17
. This effect is partly due to the higher average implant age for pacemaker patients 
than for those who received an ICD 
17
. Recently, shock therapy has been shown to increase 
mortality risks. The most common cause of death among patients receiving shocks was 
progressive heart failure 
37, 42
. One potential explanation could be that shock therapy induces 
injury to the heart. Another could be that patients who are sicker and have poorer functional 
status more often experience ventricular arrhythmias and therefore receive shock therapy 
43
. 
 
1.5 ICD KNOWLEDGE  
There is no single definition of knowledge. In dictionaries it is defined as three components: 
(1) facts, information and skills acquired by a person through experience or education; (2) the 
sum of what is known in a field; (3) awareness or familiarity gained by experience of a fact or 
situation 
44
. 
It has been shown in several studies that there is an unawareness of device benefits and 
indications for ICD implantation among physicians working in Cardiology and Internal 
Medicine and among general practitioners 
45-49
. Furthermore, knowledge regarding the legal 
and ethical aspects surrounding therapy deactivation has also been shown to be low. In one 
study that surveyed physicians working in Cardiology, Internal Medicine and Geriatrics 
departments over 40% physicians incorrectly stated that ICD deactivation is illegal, and 
almost one-fifth thought deactivation was unethical. The physicians who thought deactivation 
was illegal were more likely to be general internists or geriatricians. However, if reassured 
about the legality of discontinuing ICD therapy, as many as 91% of the same respondents 
said they would be willing to engage in such a discussion with a dying patient 
50
. 
Geriatricians and general internists had insufficient information about device deactivation; 
importantly, they were not able to identify the painful nature of shock therapy 
51
. 
Patient knowledge about ICD indications or the benefits of their ICD treatment is also low. 
As many as one-third of participants in one study reported “unknown” or “no” benefits of 
their ICD 
52
.  
Intervention programs – including: clinical tools, education, and standardized documentation 
templates in the electronic medical record – can increase rates of deactivation 53. Early and 
structured education for all healthcare professionals is essential to be able to deliver a better 
quality of care for dying patients 
54
. All physicians working with ICD patients need better 
knowledge about ICD functions in order to initiate and provide discussions about 
deactivation in terminally ill patients 
55
. 
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1.6 CARE IN END OF LIFE  
The care of a patient at the end of life sometimes involves full actions with all treatment 
available but in the majority of patients, care at the end of life shifts to palliation 
56-59
. The 
definition of palliative care by the World Health Organization (WHO) includes improved 
QOL, pain relief and management of other physical symptoms and psychosocial and spiritual 
issues which can affect patients who suffer a life-threatening illness 
60
. Palliative care has 
long been a well-established option for patients affected by terminal malignancy. While 
cancer-related pain is well known among physicians, the incidence of pain in patients with 
other serious illnesses is often underappreciated. It is common for patients with advanced 
heart failure to have pain. One study reports such pain in up to 84% of patients with advanced 
heart failure 
61
. An early integration of palliative care improves QOL, but can also have a 
possible mortality benefit 
62, 63
. Heart failure patients at the end of life need relief from 
symptoms such as dyspnea, uremia, and depression, but they can also have a need for ICD 
deactivation or other mechanical circulatory support devices 
64
. 
Prediction of death can be difficult, especially for patients with heart failure. This is due to 
heart failure’s disease trajectory which causes the clinical course for each individual to be 
unpredictable. The heart failure condition is characterized by recurrent episodes of 
deterioration accompanied with a difficulty in anticipating the terminal phase (Figure7). 
Death is often sudden 
54, 65-67
. Patients with advanced cancer have a more linear decline and 
have traditionally been the model for approaches to end-stage disease 
68-70
. Studies have 
found that only 16% of the participating physicians said they could predict death at 6 months 
in heart failure patients 
71
; furthermore, when these patients predict their own death, they tend 
to be over optimistic 
72
. 
 
Figure 7. Trajectories of decline. Reproduced from BMJ, Murray SA and Sheikh A, 336, 958-9, 2008, with 
permission from BMJ Publishing Group Ltd. 
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1.7 LOCATION OF DEATH  
Studies have shown that patients with heart failure and ICD die in hospital to a greater extent 
than those not treated with an ICD 
73, 74
. Among those who die in a health care environment, 
the majority die in hospital and only a few in nursing homes or hospices 
75
. 
 
1.8 DO NOT RESUCITATE  
Most deaths are preceded by a long period of illness and by delivery of end-of-life care 
76
. 
When a patient’s health status deteriorates, the care shifts from lifesaving to palliative. 
Advance directive (AD), a legal document commonly used in USA, reflects the patient’s 
goals, values, and wishes about their future healthcare. It goes into effect when a patient is 
incapacitated and unable to speak for him or herself in order to fulfill the patient’s desires 
related to end-of-life care.
77
 A Do-Not-Resuscitate (DNR) order is a request not to have 
cardiopulmonary resuscitation (CPR) when suffering from a cardiac arrest. A DNR order 
may be a part of an AD or when a patient's health status deteriorates it can be a decision 
issued by a physician usually together with the patient or family 
78
. Even when ICD patients 
had an AD, very few (2%) mentioned the ICD or its deactivation. This suggests that 
physicians not only have to discuss this matter with patients, they also need to encourage 
patients to address ICD management specifically 
79, 80,81
, but AD are rarely used in 
Scandinavian countries 
82
 and such a document is not legally binding in Sweden 
83
. 
Significant differences exist between Europe and North America in the management of end 
of life and the proportion of deaths preceded by a DNR order. These differences are 
characterized by wide variations between and within countries in Europe as well as between 
individual units 
84
. In southern European countries, treatment withdrawal in the Intensive 
Care Unit (ICU) is less common and CPR is more often used, as compared with northern 
European countries 
85
.  
 
1.9 DEACTIVATION  
Considering deactivation of ICD therapy should take place when prolonging life is no longer 
the goal of care. ICD shocks can be physically painful and psychologically stressful and are 
therefore inconsistent with care in end of life. Deactivation of ICD therapy is both ethical and 
legal. No differences exist between refusing initiation of ICD therapy and requesting its 
withdrawal 
64, 76, 81, 86
. Deactivating an ICD does not cause death; it allows the natural disease 
trajectory to occur 
87
. Shock deactivation can be carried out either by using a special clinical 
magnet for temporary deactivation or permanently deactivation with a programmer 
76, 81, 88, 89
. 
The incidence of shocks at end of life is not well studied. During the last 24 hours before 
death, 12% of patients in one study received shock treatment 
90
. In another study, family 
members reported that 6% of the patients received a shock within minutes before death 
91
.  
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Patients have a poor understanding of ICD function. Almost two-thirds of the patients think 
that the device needs to be explanted in order to be deactivated 
92
. Most cardiologists have 
almost contradictory beliefs about patient understanding of ICD functioning. The vast 
majority (93%) of cardiologists believe that patients understand how the ICD functions and 
are aware of the possibility to deactivate the device 
93. Furthermore, patients’ own opinions 
about deactivation differ 
94
; some patients favors deactivation 
95
, and some do not 
92, 96
. 
Deterioration in health status does not seem to effect patients’ attitudes towards deactivation. 
Even when suffering from terminal cancer, patients did not want deactivation as they were 
still hopeful of a cure and therefore prolonged life 
97. Patients’ misconception of the ICD’s 
true lifesaving capacity often manifests itself in their overestimating the ICD’s capability of 
preventing death. Patients sometimes even think about deactivation as an act of suicide 
82, 92, 
96, 98-100
. Even when patients seem to understand the role of an ICD, the decisions are made 
more intuitively than rationally. When asked about their willingness to deactivate their ICD, 
patients answered ‘no’. They were unwilling to deactivate because they believe ICD prevents 
SCD, which is understood as a preventative measure against any death. When the same 
patients are asked if they prefer a slow death, some answer ‘no’ to this as well 101. 
Discussion regarding ICD deactivation should be proactive and held continuously, before 
device implantation and at any major change in patient health status 
81, 102
. Despite this, 
physicians rarely discuss therapy deactivation with their ICD patients. This is also reflected in 
several studies in which a large majority of physicians think that deactivation of ICD in 
terminally ill patients is reasonable but rarely discuss it routinely 
103-105
. Physicians have 
limited experience; in Cardiology departments 60% of physicians had two or fewer 
conversations about deactivation with patients and families. For physicians in Internal 
Medicine and Geriatrics, the great majority (95%) reported to have had such conversations 
71
. 
Electrophysiologists are the ones who most often initiated discussions, but only 20% actually 
do engage in these discussions 
51
. Despite the lack of reported conversations, physicians do 
not feel that discussion about ICD deactivation is distressing for patients and their families. 
On the other hand physicians do believe that shock treatment is distressing 
51
. Even with this 
belief, physicians are less comfortable with ICD deactivation than discontinuing other 
lifesaving treatments 
106
. Even though some physicians admit being uncomfortable with 
deactivations they have performed 
107
 prior experience with deactivation is the strongest 
predictor of physician willingness to initiate future discussions regarding deactivation 
51, 108
. 
Some patients find it unlikely that discussions will lead to increased anxiety 
92, 95
, but others 
feel they never want to engage in such discussions 
82, 98
. Experience of shock treatment is 
associated with a more positive attitude towards discussion about it 
92
. 
 
1.10 CAUSE OF DEATH  
Most common cause of death for patients with cardiac disease is acute myocardial 
infarction, a condition that often involves life-threatening arrhythmic events 
3
. Many 
 10 
patients who develop heart failure do so as a consequence of a myocardial infarction 
109
. 
The survival rate in heart failure is comparable with many cancer diagnoses, but the 
trajectory at end of life differs between the two diagnoses 
70
. 
The most common definition of sudden death is if death occurs within one hour of the onset 
of new symptoms 
110
. Epstein et al, have developed a scheme for the classification of death 
which is used in trials of antiarrhythmic treatments, using the following categories: primary 
organ cause, temporal course, documentation, operative relation and system relation 
111
.  
Cardiac death is the major cause of death among ICD patients 
7, 74, 112, 113
. Mode of death 
was assessed for a total of 320 deaths of ICD patients participating in trials of Medtronic. The 
cause of death was: sudden in 28% of the patients, non-sudden cardiac death in 49% and 22% 
were regarded as non-cardiac deaths 
113
. The arrhythmic incidence at death in the ICD 
population is not well studied, and the few studies that have been done have shown that VT 
or VF occurred in 28-66% of patients before death 
113-115
. 
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2 AIM 
 
OVERALL AIM: 
The overall aim of this thesis was to study patients with implantable defibrillator in end of life 
as well as physicians’ knowledge about ICD therapy and compliance to guidelines 
concerning ICD management. 
 
 
SPECIFIC AIM: 
I. To analyze explanted ICD from deceased patients to assess the incidence of ventricular 
tachyarrhythmias, the occurrence of shocks, and possible device malfunction before death. 
II. To investigate end of life in ICD patients with a DNR order, with respect to location of 
death; duration between DNR order and therapy deactivation; or DNR and time of death. 
III. To assess the levels of knowledge concerning ICD therapy among physicians active in 
Cardiology, Internal Medicine and Geriatrics. 
IV. To investigate if deactivation of shock therapy in ICD patients at end of life has increased 
since publication of new guidelines on ICD management. 
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3 MATERIAL AND METHODS 
3.1 STUDY I 
The study prospectively enrolled 130 ICD devices during the inclusion period from 26 
pathology departments. Demographic data were obtained from patients’ medical notes, The 
Swedish ICD and Pacemaker Registry and The National Board of Health and Welfare. Death 
certificates which state location, time and cause of death, were obtained from the Swedish 
Tax Agency. Autopsies, if performed, were also collected. 
The time of death was established from medical notes for patients who died in hospital. Time 
of death for patients who died at home was assessed from death certificates together with 
notes from palliative care teams when available. If death was witnessed the time was 
considered to be correct. 
All available intracardiac electrograms (EGM) from the last 24 hours were retrieved from the 
ICD. After analysis from the manufacturer, five devices were excluded due to inaccessible 
data. Three investigators – two of whom were blinded to patients’ medical history 
individually reviewed and analyzed all arrhythmias. If there was a disagreement of origin of 
the arrhythmia, a fourth blinded investigator proceeded and consensus was made if three out 
of four investigators agreed upon the origin. The incidence of ventricular tachyarrhythmia 
and shock treatment within the last 24 hours of life was recorded. If the patient had VT or VF 
present within 1 hour of death and if the arrhythmia was classified as the primary cause, it 
was classified as an arrhythmic death. Definition of an arrhythmic storm was the occurrence 
of three or more episodes of VT/VF within a 24-hour period 
20
. 
To classify the cause of death, two investigators used a modified classification scheme made 
for ICD patients in arrhythmia trials 
111
. The classification of device function depended on 
success in diagnosis, treatment given, and also if there was any evidence of lead malfunction.  
 
3.2 STUDY II 
This study is a descriptive analysis of 65 deceased ICD patients all with a DNR order present 
before death. The study population was drawn from the 125 patients in study I, and included 
all those with a written DNR order or who were in palliative. 
Patients’ location of death were identified – i.e. home, nursing home, hospice or in hospital. If 
a patient died in hospital, the type of hospital – university or non-university – as well as the 
specialty of the ward in which the patient was admitted when death occurred was also 
identified. A hospital was defined as a university hospital if the hospital had an affiliation 
with a university and provision of clinical education for medical students in addition to 
delivering patient care. Ward specialty was categorized as Cardiology, Medicine (including 
Infection, Oncology and Intensive Care Unit), Surgery and Geriatrics. 
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The time of death for patients dying in hospital was established from medical notes and from 
death certificates. For patients dying at home, the time of death was assessed from the death 
certificate and, if available, notes from the palliative care team, if death was witnessed, the 
time of death was considered as correct. The time from the decision to issue a DNR order and 
therapy deactivation as well as time to death were analyzed.  
Date of deactivation was collected from medical notes together with information retrieved 
from the post-mortem interrogation of the ICD devices. Shock treatment within 24 hours of 
death was classified as shock at end of life. In addition to the occurrence of any shocks, we 
assessed the number of shocks received during the last 24 hours of life. Classification of 
death was made using the same model as in study I. 
 
3.3 STUDY III 
This is a cross-sectional comparative study. A questionnaire was constructed by the research 
group and distributed to physicians in Cardiology, Internal Medicine and Geriatrics 
departments, the three most common ward specialties in study I and study II. In the early 
phase of item construction three focus groups discussions were held with physicians from all 
three specialties. The focus groups were semi-structured and focused on necessary ICD 
knowledge for a physician working in each specialty. The first item pool was modified after 
tested on ten clinical ICD experts. The instrument underwent a pilot test with physicians in all 
three specialties within Danderyds Hospital. Most respondents felt that the questionnaire was 
clearly worded and well designed. The majority agreed that the instrument measured the level 
of knowledge regarding ICD treatment. After minor revisions based on the pilot results, the 
instrument consisted of 51 items and was considered to have a good face and content validity. 
Twenty of those 51 items were specific knowledge questions, sixteen were related to 
international guidelines awareness and 14 were of a descriptive nature.  
Level of sufficient knowledge was defined in a weighting process by the research group and 
by 10 clinical ICD experts. It resulted in nine questions viewed as necessary knowledge for 
physicians who care for patients with ICD. To achieve sufficient knowledge on the 
questionnaire the respondents had to answer seven out of the nine necessary knowledge 
questions correctly. 
A stratified nationwide cluster sampling of hospitals was performed in which hospital size 
and geographic spread were taken in to account. Written consent was obtained from each 
clinical director. In order to maximize the response rate the investigators arranged with the 
directors in each clinic to attend a regular closed meeting with the physicians in which 
questionnaires were handed out and collected manually. The participants had in most cases 
no prior knowledge about the distribution of the survey until the meeting started. 
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3.4 STUDY IV 
This is a descriptive study drawn from two cohorts of ICD patients, all of whom died in 
Swedish hospitals before and after the implementation of international guidelines on 
management of ICD patients nearing end of life, which were published in 2010 
76, 81
.  
Study agreements were obtained from all participating hospitals, and the medical records 
from the final 24 hours of life were obtained for all patients. Data from the Swedish ICD and 
Pacemaker Registry and death certificates, which state time and location of death, were 
obtained from the Swedish Tax Agency.  
Type of hospital and ward specialty in which the patients died was identified. Definition for 
university hospital was the same used in study II. Type of ward specialty was categorized as 
Cardiology (including Cardiac Intensive Care Unit and Thoracic Intensive Care Unit) or Non-
Cardiology (including Medicine, Intensive Care Unit, Acute and Emergency Department and 
Geriatrics). Patients who died in nursing home, hospice or at home were excluded. Patients 
who had their ICD explanted or deactivated more than 1 month prior to death were also 
excluded. 
The population for group 1 was drawn from the 125 patients in study I who died between 
2003-2010 before the guidelines where published. It consists of the 89 patients who died in 
hospital. During 2014, there were a total of 464 ICD patients who died in Sweden. Of those, 
253 died in hospitals and 246 of these patients were included in group 2. One out of 63 
hospitals with seven patients decided not to participate in the study. 
The same classification of death used in study I was used in group 2 and performed by the 
same two investigators, with an additional investigator in cases of disagreement.  
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4 STATISTICAL ANALYSIS 
Continuous variables are presented as mean and standard deviations (SD) or median with 
Interquartile Range (IQR) as appropriate and for categorical variables percentages or as 
confidence interval of proportions.  
Differences between means were tested using independent t-test. For between group 
comparisons, we employed Mann-Whitney test for continuous variables, Pearson chi-square 
or Fisher exact tests for smaller sizes were applied to categorical variables. One-way analysis 
of variance (ANOVA) was used to compare means between groups.  
A statistical power analysis for sample size estimation was performed for each study. 
Statistical significance was set at two-sided p less than or equal to 0.05. All statistical analysis 
was performed using SPSS software Version 20-22. 
 
4.1 ETHICAL CONSIDERATIONS  
Study I, II and IV were approved by the Regional Ethics Committee (2008/1527-31/4, 
2014/1787-32/4).  
An ethical approval for study III was sought but the Ethics Committee did not consider an 
ethical application necessary, as the questionnaire involved healthcare professionals only and 
not patients. 
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5 RESULTS 
5.1 STUDY I 
This is a descriptive study of 125 ICD patients who died during 2003-2010 in Sweden. 
Deactivation of therapy 24 hours before death was done in 25 cases with no further 
possibility to detect an arrhythmia in these patients. Results regarding VT/VF at 24 hours are 
therefore based on a study population of 100 patients (Figure 8). 
 
Figure 8. Inclusion, exclusion, arrhythmia detection and shock therapy given at 24 hours and 1 hour before 
death. EOL indicates end of life; ICD, implantable cardioverter defibrillator; and VT/VF, ventricular 
tachycardia/ventricular fibrillation. *Change in programming during the last 24 hours. Circulation. 2014 Jan 
28;129(4):422-9. Wolters Kluwer Health Lippincott Williams & Wilkins© No modifications will be permitted.  
The majority (82%) of patients had received an ICD due to secondary prevention. Device 
implantations were performed between 1998-2010. Just over one-third (35%) of those 
patients had CRT-D devices. Baseline characteristics are presented in Table 1. 
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Table 1. Baseline characteristics. Circulation. 2014 Jan 28;129(4):422-9. Wolters Kluwer Health Lippincott 
Williams & Wilkins© No modifications will be permitted  
 
Values are listed as values n (%)  
* Based on international classification of diseases in the medical notes. Not cause of death. 
A DNR order accompanied 52% of the patients. The vast majority of the patients were treated 
in a care facility, seventy-one percent of which in hospital, and only 19% of the patients died 
at home.  
Ventricular arrhythmia (VT/VF), was found in 33 (35% (95% CI 25%; 46%)) patients during 
the last hour, and shock was delivered in 27 (31%) patients. An arrhythmic storm was evident 
in 24 (24%) patients and 79% of them received shock treatment.  
Patients receiving shock often had many shocks; 45% had 1-2 shocks and 55% had 3 shocks 
or more. There were 10 (32%) patients who each experienced more than 10 shocks.  
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ICD therapy was still active in 42 (65%) of the 65 patients with a DNR order and 10 (24%) of 
these patients received shock therapy during their last 24 hours. The number of shocks is 
presented in Table 2. 
Table 2. Distribution of shocks in patients with DNR order*. Circulation. 2014 Jan 28;129(4):422-9. Wolters 
Kluwer Health Lippincott Williams & Wilkins© No modifications will be permitted. 
 
DNR indicates Do-Not-Resuscitate 
* All DNR orders written before shock treatment  
† Inadequate shock treatment due to oversense 
‡ Inadequate shock treatment due to Atrial fibrillation 
Inappropriate therapy was given to 4 (13%) patients. For the majority of patients, there was 
no evidence found suggesting that they, their family or their health care professionals had 
recognized that shock was delivered. However in 39% of patient cases, a notification was 
found which stated that the health care provider had recognized the shock treatment or that 
the patient had showed signs of pain or stress during the last hours, which is possibly 
indicative of shock therapy.  
Cardiac death (59%) was found to be the most common cause and heart failure (37%) the 
most specific cause of death. Arrhythmic death was the primary cause in 13% of patients. For 
23% of patients the death was classified as sudden. 
 
5.2 STUDY II 
All 65 patients had a DNR order and died between 2003-2010. Secondary prevention was 
indication for the initial ICD implantation in 78% of patients.  
Hospital was the location of death for 86% of patients. Many of those were university 
hospitals. All but two patients had access to healthcare assistance during the last days of life. 
For one patient the location of death was unknown (Figure 9). 
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Figure 9. Location of death and active or deactivated therapy in 65 patients with a DNR order. *One patient's 
location of death is missing. †Medicine ward including Oncology (1), §Medicine ward including Infection (1), 
Intensive Care Unit (2). ‡Medicine ward including Intensive Care Unit (1). $Medicine ward including Oncology 
(1). ICD indicating Implantable Cardioverter Defibrillator. Reprinted from Int J Cardiol. 2015 Mar 1;182:440- 
182, Kinch Westerdahl et al, Defibrillator patients should not be denied a peaceful death, Copyright 2015, with 
permission from Elsevier. 
During the last 24 hours, as many as 24% ( 95% CI,11%-37%) of patients received shock 
treatment despite the decision to refrain from resuscitation (Table 3). 
Table 3. ICD therapy programmed ON or OFF in different locations (n=65). Reprinted from Int J Cardiol. 2015 
Mar 1;182:440- 182, Kinch Westerdahl et al, Defibrillator patients should not be denied a peaceful death, 
Copyright 2015, with permission from Elsevier.. 
 
Values are listed as values n (%)  
*Shock during the last 24h for patients with ICD ON 24h 
†1 Aborted shock 
Deactivation was performed in 49% of the 65 patients, most of them within 24 hours of a 
DNR order, but for 19% a week or more passed between decision of DNR and deactivation. 
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The durations between DNR order and death for patients receiving shock therapy are 
presented in Table 4. 
Table 4. Hospital, ward specialty and number of shocks (n=10). Reprinted from Int J Cardiol. 2015 Mar 
1;182:440- 182, Kinch Westerdahl et al, Defibrillator patients should not be denied a peaceful death, Copyright 
2015, with permission from Elsevier. 
 
ICU indicating Intensive Care Unit 
DNR indicating Do-Not-Resuscitate order 
Cardiac deaths were the cause in about half (52%) of patients in which heart failure was the 
most common (42%) specific cause. For the non-cardiac cause, malignancy (23%) was most 
common. 
 
5.3 STUDY III 
A total of 432 surveys were distributed and 430 collected. Only two physicians did not 
submit the survey after completion, resulting in a response rate of 99.5%. Distribution was 
done in 14 (78%) of 18 of the sampled hospitals, five (36%) of which were university 
hospitals. Out of the sampled hospitals, four either did not respond or declined participation 
to the enquiry of participation.  
A total of 83% of physicians said they had earlier experience with ICD patients, but 68% 
estimated their level of knowledge about ICD treatment to be low. Baseline characteristics 
are presented in Table 5. 
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Table 5. Baseline characteristics.  
 
Data given as mean ± SD or n (%) 
Total number of responses for each question listed as values n 
ICD indicating Implantable Cardioverter Defibrillator 
A significant difference in level of knowledge was found between physicians in different 
specialties. A total of 41% of all physicians reached sufficient level of knowledge according 
to the predefined criteria of necessary knowledge for the ability to manage patients with ICD. 
The physicians working in Cardiology departments scored higher than other physicians and 
had an average score of 6.79 ±1.75 out of nine possible correct answers. Compared to other 
physicians they earned 1.82 (CI 1.43-2.20) points higher. Physicians in Internal Medicine 
scored significantly (p<0.001) better than physicians in Geriatrics. Furthermore, physicians in 
university hospitals had significantly (p<0.001) higher scores with a mean of 6.23 ± 1.99 than 
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non-university hospitals. Attending physicians had higher scores (p<0.001) compared to 
fellows in all fields (Table 6). 
Table 6. Mean score between level of education and specialty. 
 
Total number of responses for each group listed as values n 
Only 76% of physicians indicated shock treatment as being painful if experienced by a 
conscious patient. This knowledge was indicated even less among physicians in specialties 
other than Cardiology: 69% in Internal Medicine and 67% in Geriatrics. An insecurity 
regarding SCA was shown in that 40% of all doctors said they did not know how to handle an 
ICD patient with SCA and 29% agreed with the following statement: “You can not externally 
defibrillate a pulseless ICD patient.” See Table 7 for the results on all nine weighted 
knowledge questions. 
The two internationally accepted abbreviations used for implantable defibrillators are ICD 
and CRT-D. Only 24% of respondents identified both abbreviations, and 10% of them failed 
to identify any. Just over half (51%) of physicians in Cardiology, 14% of physicians in 
Internal Medicine and 6% in Geriatrics could identify both. When asked about their 
awareness of international ICD guidelines, many physicians – 77% of all and 38% of them in 
Cardiology – estimated it to be poor or very poor. Patients with ICD treatment have some 
legal restrictions on the conditions under which they are allowed to operate a motor vehicle. 
Almost half (49%) of the respondents did not know that it is prohibited for an ICD patient to 
drive commercials vehicles.  
In regards to the following statement: “Patients always have the right to refuse treatment, 
seventy-three percent agreed (“I agree completely”) while only 3% disagreed (“I completely 
disagree”). 
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Table 7. Sufficient knowledge between medical specialties (correct answer in seven out of nine necessary 
questions). 
 
Values are listed as values n (%)  
Correct answer for each question listed within brackets 
ICD indicates Implantable Cardioverter Defibrillator 
  
 24 
5.4 STUDY IV 
Inclusion, exclusion criteria and distribution of DNR order and deactivation is shown in 
Figure 10. 
 
Figure 10. Inclusion, exclusion.Values are listed as values n (%) DNR indicating Do-Not-Resuscitate; ICD 
indicating Implantable Cardioverter Defibrillator; * Other Care facility indicating hospice or nursing home. 
No significant difference was found between groups regarding age or gender distribution. Co-
morbidities between the groups were similar, with the only significant difference found for 
hypertension (p=0.013), which was more frequent in group 2. The primary prophylactic 
indication for ICD treatment significantly (p<0.001) differed between groups. Baseline 
characteristics are presented in Table 8. 
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Table 8. Baseline characteristics. 
 
Values are listed as values n (%)  
† Based on international classification of diseases in the medical notes. Not cause of death. 
Patients in group 1 died in 26 different hospitals, 10 of which (38%) were university 
hospitals. For group 2, university hospitals represented 11 (17%) out of 63 total hospitals. 
There was a similar distribution in both cohorts of patients’ treatment location: for groups 1 
and 2 respectively, 37% versus 31% of patients were treated in Cardiology and 63% versus 
69% were treated in Non-Cardiology wards (Table 9).  
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Table 9. ICD therapy deactivation and DNR in different locations. 
 
Values are listed as values n (%)  
* Including Cardiac Intensive Care Unit and Thoracic Intensive Care Unit 
† Differences in deactivation within group 2 between Cardiology vs. Non-Cardiology was significant 
(p=0.038). DNR indicating Do-Not-Resuscitate order; ICD indicating Implantable Cardioverter Defibrillator. 
Cardiac death was the most common cause and heart failure was the most common specific 
cause of death with no significant difference between groups. More system related deaths 
were found in group 1 than in group 2. Technical malfunction in group 2 is based on medical 
notes and not actual device interrogation as it is in group 1. 
Over half (54%) of the patients in group 1 had a DNR order, and 52% of them had shock 
therapy deactivated. In group 2 there were 73% of patients who had a DNR order, and shock 
therapy was deactivated in 67% of patients. Although there were a general increase in shock 
deactivation between groups for patients with DNR the difference was not significant 
(p=0.062), but increased significantly (p=0.016) between group 1 and group 2 among patients 
treated in Cardiology wards (Table 9). A significant difference (p=0.038) in deactivation rate 
for DNR patients was found within group 2 between patients treated in Cardiology vs. Non-
Cardiology wards. No such difference was found within group 1. Deactivation of shock 
therapy was performed after two days or more in about 40% of patients in both groups. 
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6 DISCUSSION 
We have shown that patients with ICD often have ventricular tachyarrhythmia and suffer 
from shocks close to death. Patients were at end of life and many had a DNR order; despite 
this ICD shock therapy remained active in the majority of the patients. In hospital death was 
most common and the majority of patients were treated in Non-Cardiology wards. There was 
a lack of basic knowledge of ICD therapy among physicians. Knowledge gaps were most 
considerable among physicians in Internal Medicine and Geriatrics departments. Newly 
published international guidelines on the management of ICD patients in end of life have had 
some impact but mainly among physicians in Cardiology. 
 
Ventricular tachyarrhythmia 
In study I we have shown that ventricular tachyarrhythmia is not uncommon in dying ICD 
patients. One-third of the patients had VT or VF and almost one-fourth had arrhythmic storm 
during the last day of life. Many terminally ill patients develop conditions pre-disposing them 
to arrhythmia 
76. It is well know that heart failure patients’ deaths often come suddenly 54, 65-
67
. New York Heart Association class (NYHA) III is an independent predictor of shock 
treatment 
116. The patients’ NYHA class is not known in our studies; however, while over 
50% of all patients had EF<30%, one can assume NYHA class to be III or less. The temporal 
cause of death was similar in both study I and study IV, comparable to the results in MADIT-
II, in which death was sudden for over one-fourth of patients 
74
. Cardiac death and heart 
failure, was the most common cause of death in study I and study IV. This result shares a 
similar distribution to previous ICD studies 
113, 117
. Arrhythmic death was the cause of death 
in only 13% of patients. 
 
Shock  
Almost one-third of the patients in study I received shock therapy during the last hour of life 
and those who received shock often received multiple shocks. Despite a DNR order in the 
majority of patients, shock therapy was active in half of the patients 24 hours before death, 
exposing patients to a risk of unnecessary shock treatment. In study II, in which all patients 
had a DNR order, one-fourth of patients received shock therapy during the last day of life.  
Most patients find ICD shocks painful and frightening, leading to lower QOL, with anxiety 
and distress 
22, 23, 26-28, 32, 118, 119
. It is not known to what extent shocks cause pain in dying ICD 
patients, but healthcare providers have a responsibility to minimize pain in palliative patients 
60
. It is imperative that patients understand that therapy deactivation is an option. The 
majority of physicians in study III do acknowledge that shocks are painful for a conscious 
patient, but one-third of physicians in Medicine and Geriatrics did not. The unawareness of 
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this important complication could possibly prolong the time before patients receive adequate 
care and support in case of shock. 
 
DNR order and ICD patients at end of life  
When a patient life is ending and illnesses can’t be cured, the focus of care shifts from 
curability to palliation. Palliative care includes relieving the patient from pain and other 
distressing symptoms 
60
. The majority of patients in study I and study IV had a DNR order, 
confirming earlier studies which show that dying patients commonly have DNR order 
58, 59
. 
The purpose of a DNR order is to support patient autonomy and to prevent non-beneficial 
interventions. Old age, perception of a poor prognosis and impaired functional status have 
shown to correlate with patients’ wish to not want resuscitation 57, 120. Physicians’ willingness 
to make decisions regarding DNR is influenced by their experience as well as a history of 
prior end of life discussions 
51, 108, 121
.  
Patients’ involvement in the DNR process is not known in our studies. Prior studies have 
shown an inconsistency in patients’ willingness to engage in end of life discussions; there are 
those who want to be involved in such discussions and those who do not 
92, 95, 122, 123
. Despite 
this, physicians often make decisions regarding DNR and deactivation without involvement 
of patients or family, an approach more common in Sweden than in other European countries 
76, 104, 124, 125
. Not involving the patient is probably a decision made based on the assumption 
that resuscitation is futile for the patient concerned. Interestingly, there is an inconsistency 
about patients’ preferences for therapy outcome. Some studies suggest that treatment 
resulting in improved symptoms is of greater importance than treatment resulting in longer 
survival while others show that patients preferred survival longevity over QOL 
96, 126
. 
Nevertheless, patients’ involvement in end of life conversations leads to less intensive 
medical interventions, fewer admissions to ICU and fewer patients undergoing CPR 
127
. ICD 
due to primary prevention, advanced age, earlier experience of shocks or an awareness of 
being at the end of life are characteristics shown to more easily enable discussions with 
patients 
80, 82, 95, 99, 122
 
 
Deactivation  
Almost half of the patients with a DNR order in study I and one-third of the patients in study 
IV (group 2) died with active ICD therapy. Although a DNR order is not equal to ICD 
deactivation, it is an essential factor in initiating a discussion 
76
.  
The exact number of patients who died with active therapy and who had a prior conversation 
about deactivation in our studies is not known. Communication regarding therapy 
deactivation is complicated, but should be done early, systematically and continuously over 
the course of a patient’s illness. Physicians do acknowledge the importance of discussing 
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deactivation with dying ICD patients, even though many are reluctant to engage in these 
discussions 
87, 103
.  
Both patients and physicians find ICD deactivation morally equivalent to a DNR order in that 
deactivation allows the patient to die of the natural progression of their underlying disease 
76, 
89
. Physicians believe that patients know that deactivation is a possible option, but most 
patients are not aware of this 
92, 93, 100
. Physicians and patients are also unaware about the 
function of the ICD if deactivated, which contributes to this issue’s complexity 50, 51, 82, 95, 97, 
98
.  
Patients always have the right to refuse treatment and withdrawal of ICD therapy at any time 
36, 76, 81, 128
. The majority of physicians in study III agreed to this as well as the ethicality and 
legality of deactivation in a terminally ill patient, which is inline with international guidelines 
66, 76, 81, 89
.  
Study IV showed that the number of deactivations has increased for DNR patients admitted to 
hospital since the start of study I, though the increase was not significant. For DNR patients 
treated within Cardiology however the increase over the years was significant. Furthermore, 
DNR patients who were in group 2, treated in Cardiology wards and who died in 2014 all had 
higher rates of deactivations compared with those who were treated in Non-Cardiology 
wards. These results imply that international guidelines possibly helped in the management of 
patients in Cardiology but did not help for patients managed in other specialties. During the 
last 5-10 years, the subject of ICD deactivation has been highlighted more frequently. This 
could have contributed to a higher awareness among physicians in Cardiology. 
 
Location of death  
The majority of patients in study I and study II as well as 53% of all 464 ICD patients who 
died during 2014 (group 2) died in hospital. This confirms the results of earlier studies that it 
is common for ICD patients to be admitted to hospital before death 
73, 74
. Many of the 
hospitals in our studies were university hospitals. This did not affect therapy deactivation per 
se; in study II more than half of the patients having therapy still active at death were 
inpatients in an university hospital. Those patients were most commonly treated in 
Cardiology wards. DNR patients under university Cardiology care who had high cardiac 
competence still had active devices when they died. Comfortingly though, in study IV we 
showed an increase in deactivation rates for DNR patients treated in Cardiology. Hopefully 
this will be true also for patients treated in Non-Cardiology wards when guidelines have been 
implemented in clinical practice. All healthcare professionals involved in the care of patients 
with ICD are obligated to identify key medical issues, including unnecessary ICD therapy at 
end of life, and to support each patient at his or her request in order to save terminally ill 
patients from unnecessary discomfort. 
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ICD knowledge 
Overall, basic ICD knowledge among physicians was low, only 41% in study III reached the 
predefined criteria for sufficient level of knowledge to manage patients with ICD. Though 
physicians in Cardiology scored highest, one-third of them still did not reach a sufficient 
level. This result implies a need for further educational efforts. The most significant 
knowledge gaps existed however among physicians in Internal Medicine and Geriatrics, in 
line with earlier results 
51., 129
. With the increasing number of ICD patients and majority of 
these patients treated in Non-Cardiology wards, the cardiologist will no longer be able to 
follow each patient. This may well shift much responsibility to primary care physicians who 
will then be obligated to understand fundamental technical features of these devices. Study III 
shows that sufficient ICD knowledge was only achieved for less than one-third of the 
physicians in Internal Medicine and less than one-fifth in Geriatrics. The vast majority of all 
respondents in study III said they had experience treating ICD patients, confirming the results 
from study II and study IV that ICD patients are admitted to a variety of wards.  
In the patients’ medical records, two abbreviations, CRT-D and ICD, are commonly used to 
identify that a patient has a defibrillator implanted. The results in study III showed that many 
physicians fail to identify these abbreviations, which could lead to misconceptions and 
possibly to an inability to identify that a patient has an ICD. The recently introduced S-ICD 
adds to the list of abbreviations physicians needs to know. Possibly it would have been easier 
if all the abbreviations contained a varying supplemental abbreviation to indicate specific 
treatment, for example ICD, ICD-CRT and ICD-S. 
Physical contact with a patient during shock is not associated with any danger 
20
. This is a 
fact of which one-third of the physicians in Geriatrics and one-fifth of the physicians in 
Internal Medicine in study III were unaware. This could result in resistance to comfort 
patients during shock therapy. Even worse, the misconception could result in the possibility 
of a physician not performing adequate CPR on ICD patients.  
The need for external defibrillation is low, but such defibrillation can be essential if the ICD 
fails to convert an arrhythmia. Almost one-third of all physicians falsely stated that one can 
not externally defibrillate a pulseless ICD patient, and 40% said they did not know how to 
handle an ICD patient with cardiac arrest. This may potentially result in delayed or possibly 
inadequate treatment. Comfortingly though, almost all of the attending physicians within 
Cardiology said they knew how to handle SCA in ICD patients. 
Some physicians are not aware of the ICD function when it is deactivated. In study III, over 
one-third of physicians’ working in Non-Cardiology departments thought deactivation of 
shock therapy in an ICD weren’t possible. Furthermore, one-third of all physicians’ thought 
that deactivation would also turn off the pacing function regardless of the method used i.e. 
programmer or magnet application. This can lead to reluctance to perform therapy 
deactivation in patients at end of life thus exposing them to an unnecessary risk of shocks.  
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Guideline compliance  
ICD treatment prevents SCD and improves total survival both in secondary prevention as 
well as in primary prevention populations 
36
. Only half of the physicians in study III knew 
both indications. When physicians were asked about their awareness about international 
guidelines, seventy-seven percent of all physicians and 38% in Cardiology, said they had 
little or no knowledge of them, confirming earlier data that showed a low awareness of ICD 
guidelines, particularly in physicians working outside Cardiology 
45, 46, 48, 50
.  
The national guidelines from the National Board of Health and Welfare in Sweden have in 
2015 highlighted the question regarding deactivation in ICD patients at end of life 
13
. 
International guidelines emphasize that advanced care planning should include deactivation 
of ICD therapy 
76, 81, 130
. Furthermore, it has been shown that if hospitals have an ICD 
deactivation policy the rate of ICD deactivation may increase 
91
. 
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7 CONCLUSIONS 
 More than one-third of patients had a ventricular tachyarrhythmia within the last hour 
of life, 31% received shock treatment and 24% had an arrhythmic storm during the 
last 24 hours of life.  
 In ICD patients cardiac death was the primary cause and heart failure the specific 
cause of death in the majority of cases while an arrhythmic cause was found in 13%. 
 The ICD remained active in half of the patients with a DNR order; almost one-fourth 
of these patients received one or more shocks in the last 24 hours of life. 
 ICD patients with a DNR order and active shock treatment had a median of four days 
or more between DNR decision and death.  
 For more than one-third of patients with ICD therapy deactivated two days or more 
elapsed between DNR decision and decativation. 
 Device malfunction was found in 3% of cases and was mainly attributable to 
undersensing of ventricular fibrillation. 
 Most ICD patients died in hospitals, many in university hospitals. Two-thirds of those 
patients were treated in Non-Cardiology departments before death and only one-third 
of them were treated in Cardiology. 
 Test scores revealed insufficient knowledge of ICD therapy in the majority of 
participating physicians, that possibly could affect their ability to manage ICD 
patients. Physicians rate their knowledge to be low although many had earlier 
experience in treating patients with ICD.  
 The increase in therapy deactivation in ICD patients with DNR since publication of 
guidelines on ICD management at end of life is statistically significant for patients 
treated in Cardiology wards.  
 With an increasing ICD population there is an urgent call for actions to bridge the 
knowledge gap between the guidelines’ recommendations and clinical practice. 
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8 CLINICAL IMPLICATIONS  
 An increased knowledge of the incidence of ventricular tachyarrhythmia and shock 
treatment at the end of life for patients with ICD may lead to improved care and a 
lower incidence of unnecessary and painful shocks for patients close to death. 
 When a ICD patients health status detoriates significantly and a decision is made not 
to resusitate (DNR), it is imperative to discuss deactivation of the device. 
Highligtning the question of deactivation among physicians, nurses and patients may 
increase the number of future deactivations.  
 All physician involved with ICD patients have to understand fundamental technical 
features of these devices and the managment at end of life to be able to deliver best 
possible care for this exposed group of patients.  
 
9 FUTURE PERSPECTIVES 
 Discussion about end of life care in ICD patients has to be done more systematically; 
could a palliative consultations be a of any help for patients and healthcare 
proffessionals?  
 Systematically post-mortem interrogation of devices can help institutions to improve 
the quality of patient care. 
 Decreasing number of inappropriate shocks may have an influence on patient QOL 
and possibly decreasing anxiety and depression levels. Future studies may reveal this. 
 Home monitoring system and deactivation – is this the way forward – can it be done 
safe and secure? 
 The awareness of ICD guidelines and clinical management has to increase and 
disseminate knowledge beyond Cardiology. 
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10 SVENSK SAMMANFATTNING 
 
Inledning 
Patienter med hög risk att drabbas av livshotande rytmrubbningar kan i förebyggande syfte få 
en implanterbar defibrillator (ICD) inopererad. Defibrillatorn bryter hjärtrusningar med 
chocker eller sekvenser av snabba pacemaker-stimuleringar. Indikationen för ICD behandling 
är antingen att personen har överlevt ett hjärtstopp eller en livshotande kammartakykardi, s.k. 
sekundärprofylax, alternativt har en ökad risk för livshotande rytmrubbningar på grund av en 
nedsatt hjärtfunktion s.k. primärprofylax. I ett flertal studier har man kunnat visa en förbättrad 
överlevnad både i sekundär så väl som primär profylaktisk ICD behandling. Antalet patienter 
med ICD behandling ökar i hela världen och även i Sverige. Under 2014 fanns det drygt 9000 
patienter med aktiv behandling. Socialstyrelsens riktlinjer har höjt prioriteringen för ICD 
behandling vilket bidragit till den ökade implantationsfrekvens. Läkare som vårdar patienter 
med ICD måste känna till behandlingen för att kunna ge bästa möjliga vård. Även om ICD 
skyddar mot plötslig död kommer vi alla att så småningom avlida av ålderdom eller av 
underliggande sjukdom. Under 2010 publicerade internationella riktlinjer för att belysa och 
lyfta frågor som rör vården av patienter med ICD i livets slutskede. Det saknas djupare 
kunskap om vad som händer i samband med att dessa patienter avlider. Det övergripande 
syftet med denna avhandling var att studera patienter med ICD i livets slutskede samt att 
undersöka läkares kunskapsnivå avseende ICD behandling och följsamhet till riktlinjer 
gällande patienter med ICD i livets slutskede. 
 
Metod och Resultat:  
Studie I: är en observations studie där explanterade ICD dosor från 125 avlidna patienter 
undersöktes. Syftet var att studera ICD dosor för att få en ökad kunskap om kammararytmier, 
chockterapi och eventuella tekniska fel i samband med att patienter med ICD avlider. 
Resultatet visade att 71% av patienter med ICD dör på sjukhus, vanligen pga. hjärtsvikt. Det 
var 35% av patienterna som hade någon form av kammararytmi sista timmen i livet och 31% 
fick chock behandling under de sista 24 timmarna. Det var mer än hälften (52%) av 
patienterna i studien som hade en s.k. behandlingsbegränsning och där vården övergått till 
palliation. Trots det så var det 51% som fortfarande hade chockterapierna aktiva när de dog. 
Nästan en fjärdedel fick chock som en konsekvens av detta.  
 
Studie II: är en observationsstudie där de 65 patienter med beslut om 
behandlingsbegränsning från studie I ingår. Syftet var att kartlägga hur patienter med 
behandlingsbegränsning och ICD vårdas, var de behandlas när de dör, samt durationen 
mellan behandlingsbegränsning och deaktivering av chockterapier. Resultaten visar att 
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majoriteten (86%) av patienterna dör på sjukhus. Av dessa så vårdas 63% på universitetets 
sjukhus och 33% på hjärtavdelningar. Trots behandlingsbegränsning var ICD chock aktiv hos 
51% av patienterna och 24% fick chock terapier under sista dygnet. Tiden från beslut om 
behandlingsbegränsning och död hos patienter med terapier aktiva var 4 dagar (IQR 1-38). 
Hos dem med terapier avstängda, så tog det 2 dagar eller mer mellan beslut om 
behandlingsbegränsning och deaktivering för mer än en tredjedel (38%) av patienterna.  
 
Studie III: är en deskriptiv tvärsnitts studie. En enkät utarbetades i forskargruppen och delats 
ut till läkare verksamma inom kardiologi, internmedicin samt geriatrik på slumpmässigt 
utvalda sjukhus i Sverige. För att nå tillräcklig kunskapsnivå var respondenten tvungen att 
svar rätt på sju av nio viktade kunskapsfrågor. Syftet att kartlägga och jämföra kunskapsnivån 
gällande ICD behandling i allmänhet samt i livets slutskede, hos kliniskt verksamma läkare 
inom kardiologi, internmedicin och geriatrik. Resultatet visade att många (83%) av läkarna 
hade tidigare erfarenhet av att vårda patienter med ICD men att 68% ansåg att deras 
kunskapsnivå gällande ICD behandling var låg. Totalt erhöll 41% av läkarna resultatet 
tillräcklig kunskap. Läkare inom kardiologi hade signifikant högre resultat än läkare från de 
andra specialiteterna. Endast 30% av läkare inom internmedicin och 19% av dem inom 
geriatrik som nådde nivån tillräcklig kunskap jämfört med 71% inom kardiologi. 
 
Studie IV: är en observationsstudie, där två grupper av patienter med ICD som avlidit på 
sjukhus före och efter publicering av internationella riktlinjer jämförs. Grupp 1 bestod av 89 
patienter från studie I, alla avled på sjukhus under 2010 eller tidigare. Under 2014 avled total 
464 patienter med ICD i Sverige. Av dessa dog 253 patienter på sjukhus och 246 av dem 
inkluderades i grupp 2. Ett sjukhus, av totalt 63, med sju patienter beslöt sig för att inte delta i 
studien. Syftet var att undersöka om förekomsten av deaktivering av chock terapier har ökat 
efter publicering av nya riktlinjer gällande patienter med ICD i livets slutskede. Resultatet 
visade att två tredjedelar av patienter med ICD vårdas på på andra avdelningar än kardiologen 
när de dör. Beslut om behandlingsbegränsningar är vanligt, för grupp 1 54% och 73% för 
grupp 2. Deaktivering av chock ökade från 52% för grupp 1 till 67% för grupp 2. Denna 
ökning var dock enbart signifikant (p< 0.016) för de patienter med behandlingsbegränsning 
och som vårdades på kardiologen. En signifikant skillnad (p= 0.038) fanns även inom grupp 2 
för de patienter med behandlingsbegränsning, chocker deaktiverade och som vårdats på 
kardiologen jämfört med de som vårdats på andra avdelningar. Tiden mellan beslut om 
behandlingsbegränsning och deaktivering var två dygn för omkring 40% av patienterna i båda 
grupperna. 
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Slutsats 
Patienter med ICD i livets slutskede vårdas på sjukhus i samband med att de dör och två 
tredjedelar vårdas på icke kardiologiska avdelningar. ICD patienter har kammararytmier i 
samband med att de dör. Många av patienterna har en behandlingsbegränsning, men trots det 
är chockterapier fortfarande påslagna hos en stor andel av patienterna och många riskerar 
därför onödiga chocker som en konsekvens av aktiva terapier. Andelen patienter som får sina 
terapier deaktiverade har ökat men inte signifikant sedan publicering av nya internationella 
riktlinjer gällande patienter med ICD i livets slutskede. Många läkare har inte tillräckliga 
kunskaper om ICD behandling. Kunskapen är låg framförallt hos läkare som arbetar utanför 
kardiologi, men även inom kardiologen behöver kunskapsnivån höjas för att höja kvaliteten 
och säkerställa en bra vård i livets slutskede för patienter med ICD. 
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